

fldA is an essential gene required in the 2-C-methyl-D-erythritol 4-phosphate pathway for isoprenoid biosynthesis

Kia-Joo Puan^{a,1}, Hong Wang^a, Tohru Dairi^b, Tomohisa Kuzuyama^c, Craig T. Morita^{a,*}

^a Division of Rheumatology, Department of Internal Medicine and the Interdisciplinary Group in Immunology, University of Iowa, EMRB 340F, Iowa City, IA 52242, USA

^b Biotechnology Research Center, Toyama Prefectural University, Toyama 939-0398, Japan

^c Biotechnology Research Center, The University of Tokyo, Bunkyo-ku, Tokyo 113-8657, Japan

Received 2 April 2005; revised 24 May 2005; accepted 25 May 2005

Available online 13 June 2005

Edited by Richard Cogdell

Abstract Although flavodoxin I is indispensable for *Escherichia coli* growth, the exact pathway(s) where flavodoxin I is essential has not been identified. We performed transposon mutagenesis of the flavodoxin I gene, *fldA*, in an *E. coli* strain that expressed mevalonate pathway enzymes and that had a point mutation in the *lytB* gene of the MEP pathway resulting in the accumulation of (E)-4-hydroxy-3-methylbutyl-2-enyl pyrophosphate (HMBPP). Disruption of *fldA* abrogated mevalonate-independent growth and dramatically decreased HMBPP levels. The *fldA*[−] mutant grew with mevalonate indicating that the essential role of flavodoxin I under aerobic conditions is in the MEP pathway. Growth was restored by *fldA* complementation. Since GcpE (which synthesizes HMBPP) and LytB are iron–sulfur enzymes that require a reducing system for their activity, we propose that flavodoxin is essential for GcpE and possibly LytB activity. Thus, the essential role for flavodoxin I in *E. coli* is in the MEP pathway for isoprenoid biosynthesis.

© 2005 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Keywords: 2-C-Methyl-D-erythritol 4-phosphate; Flavodoxin I; *fldA*; (E)-4-Hydroxy-3-methylbutyl-2-enyl pyrophosphate; γδ T cell

1. Introduction

Two metabolic pathways exist for isoprenoid biosynthesis: the classical mevalonate pathway found ubiquitously in mammalian cells and Archaeobacteria and the recently discovered 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway (also termed the deoxyxylulose pathway) [1–3]. The MEP pathway is present in most *Eubacteria*, plant chloroplasts, and the apicoplasts of Apicomplexan protozoa such as *Plasmodium* and

Toxoplasma [4]. Both pathways lead to the synthesis of two essential metabolic precursors for isoprenoid biosynthesis, isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP). The MEP pathway consists of 7 enzymes. The last two enzymes, GcpE [5–7] and LytB [8], are the most unusual because their functional activities are rapidly inactivated by dioxygen and thus are dependent on the presence of exogenous reducing agents for their enzymatic activity (reviewed in [4]). Seemann et al. [9] has reported that GcpE in *E. coli* consists of a dioxygen-sensitive [4Fe–4S]²⁺ cluster that is required for the catalytic reduction of 2-C-methyl-D-erythritol cyclopyrophosphate into (E)-4-hydroxy-3-methylbutyl-2-enyl pyrophosphate (HMBPP).

HMBPP is a potent activator of human Vγ2Vδ2 T cells ([10,11], and reviewed in [12]) and the presence of HMBPP correlates with the ability of microbes to stimulate Vγ2Vδ2 T cells in vitro and in vivo ([13], and reviewed in [14]). Similarly, the conversion of HMBPP to IPP and DMAPP by the downstream enzyme, LytB, also strictly depends on the presence of reducing agents for its action [15]. Further studies on LytB using UV/Vis absorption and electron paramagnetic resonance reveal that it too contains a [4Fe–4S] cluster [16,17]. Thus, it has been suggested that these [Fe–S] clusters in GcpE and LytB participate in the electron transfer process maintained under a reducing environment.

A common characteristic shared by many iron–sulfur proteins is the requirement for a reducing system that permits the regeneration of reduced [Fe–S]²⁺ clusters. The reduction of oxidized [Fe–S]²⁺ could be achieved using dithionite or a stronger reductant, deazaflavin [15]. Alternatively, this reduction can be provided using the endogenous flavodoxin/flavodoxin reductase/NADPH reducing system present in prokaryotes, and in red and green algae. Flavodoxins comprise a family of small molecular weight electron transferases important for a variety of metabolic processes including nitrogen fixation, carbon dioxide fixation, and anaerobic metabolism. Two types of flavodoxins exist in *E. coli*. Flavodoxin I is encoded by *fldA* and is constitutively expressed in *E. coli* whereas flavodoxin II is encoded by *fldB* and is induced by oxidative stress [18]. Flavodoxin I has been shown to be an essential gene in *E. coli*. Flavodoxin II cannot replace flavodoxin I [18]. However, the metabolic pathway where flavodoxin I is essential is unknown. Here, we report that transposon-mediated mutagenesis of *fldA* demonstrates that flavodoxin I plays an essential role in the MEP isoprenoid biosynthetic pathway.

*Corresponding author. Fax: +1 319 335 7607.

E-mail address: craig-morita@uiowa.edu (C.T. Morita).

¹ Present address: Division of Cellular and Molecular Research, National Cancer Center, 11 Hospital Drive, Singapore 169610.

Abbreviations: DMAPP, dimethylallyl pyrophosphate; IPP, isopentenyl pyrophosphate; MEP, 2-C-methyl-D-erythritol 4-phosphate; HMBPP, (E)-4-hydroxy-3-methylbutyl-2-enyl pyrophosphate; LB, Luria-Bertani; MVA, mevalonate; PBS, phosphate buffered saline

2. Materials and methods

2.1. Construction of the DK310 *idi*-disruptant

Bacteria strains and plasmids used in this study are detailed in Supplemental Table 1. On the basis of the nucleotide sequence of the IPP isomerase gene, *idi*, from *E. coli* W3110, two oligonucleotide primers, 5'-GGAAGCTTACATGATGCTTCATGGTTTG-3' (upstream of 5' of *idi*) and 5'-GGAAGCTTTGGGAAGTTGAAACGCCGATG-3' (downstream of 3' of *idi*), including a *Hind*III restriction site (underlined) were synthesized (Sigma, St. Louis, MO) and used together with total DNA from *E. coli* W3110 to amplify *idi*. By using Taq DNA polymerase (Roche Molecular Biochemicals, Indianapolis, IN) and the protocol recommended by the supplier, a 2.5-kb fragment including the *idi* gene was amplified. The PCR fragment was digested with *Hind*III and cloned into the multi-cloning site of an *E. coli* vector pUC118 to give pUIDI.

An *idi*-disruptant, DK310, was constructed by insertion of the *Cm^r* gene (a chloramphenicol-resistance gene) into the *idi* gene. *Cm^r* gene was digested with *Aor*51HI from pACYC184 to provide a 1.3-kb DNA fragment carrying the *Cm^r* gene, which encoded chloramphenicol acetyltransferase. pUIDI was digested with *Spe*I, the recognition site of which was in the targeted *idi* gene, treated with T4 DNA polymerase, and then ligated with the 1.3-kb DNA fragment carrying the *Cm^r* gene to construct pUIDICM. A 3.8-kb linear *Hind*III–*Hind*III fragment carrying *idi* and *Cm^r* genes was isolated from pUIDICM. *E. coli* FS1576, a *recD* mutant, was transformed with the *Hind*III–*Hind*III fragment and then chloramphenicol-resistant transformants were selected on Luria-Bertani (LB) plates containing 17 µg chloramphenicol/ml. After the correct disruption was confirmed by Southern hybridization using the *idi* and *Cm^r* genes as the probes, the disrupted *idi* gene was then transduced to *E. coli* W3110 (wild-type) using bacteriophage P1. The resulting W3110 *idi::Cm^r* strain was named DK310.

2.2. Construction of DK310 (*idi⁻*) *LytB*^{G120D} mutant strains

The *idi* disruptant strain, DK310, was treated with *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine as previously described [19]. After the treatment, DK310 was transformed with the pTMV22KM plasmid that contains the genes for mevalonate kinase, phosphomevalonate kinase, and diphosphomevalonate decarboxylase all from *Streptomyces* sp. strain CL190 [20,21]. A mutant in the *lytB* gene was then isolated by screening ~20000 colonies for colonies that required mevalonate for growth. The point mutation changed glycine to aspartic acid at position 120 (GGT → GAT). This strain was named DK310 *LytB*^{G120D} (pTMV22KM). A second strain, DK310 *LytB*^{G120D} (pTMV20KM), was developed from this strain by transformation with pTMV20KM and selection on an LB plate containing CM and KM. The pTMV20KM plasmid contains the *Streptomyces* sp. genes for mevalonate kinase, phosphomevalonate kinase, diphosphomevalonate decarboxylase, and isopentenyl diphosphate isomerase. The growth properties of the two strains at 37 °C in LB liquid medium for 12 h are shown in Table 1.

2.3. Generation of DK310 *LytB*^{G120D} *fldA* mutant strain

An *fldA* mutant *E. coli* strain was generated by transposon-mediated mutagenesis of the DK310 *LytB*^{G120D} (pTMV20KM) bacteria. The bacteria were grown in LB broth to an optimal density of 0.3, chilled immediately, centrifuged, and washed three times with ice-cold 10%

glycerol. The resulting pellet was re-suspended in medium containing 10% glycerol, 0.125% (w/v) yeast extract and 0.25% (w/v) tryptone, and stored at –80 °C. Fifty microliter of these electrocompetent bacteria was mixed with 1 µl of EZ:TN™ (DHFR-1) Tnp Transposome™ (Epicentre, Madison, WI) and transferred to a 0.2 cm electrode cuvette. Transposome were electroporated into bacterial cells using a Gene Pulser II electroporator (Biorad, Burlingame, CA) set at 2500 V, 200 Ω, and 25 µF. One milliliter of SOC medium was immediately added to the bacteria after electroporation. The bacteria were incubated at 37 °C for 1 h with gentle agitation. The transposed bacteria were spread on LB plate containing 50 µg/ml trimethoprim and 1 mg/ml mevalonolactone (Sigma) at 37 °C overnight. Bacterial mutants, thus, generated were arrayed in a 96 well format and screened for the loss of bioactivity with a Vγ2Vδ2 T cell clone and for their ability to grow in the absence of mevalonate. To ensure the complete loss of activity, bacteria were further grown at room temperature for 4–7 days. Genomic DNA was isolated from mutants using a MasterPure™ DNA purification kit (Epicentre) and directly sequenced with a pair of primers specific to each end of the transposon at the University of Iowa DNA sequencing facility. DHFR-1 forward primer: GGCGGAAACATTGGATGCGG; DHFR-2 reverse primer: GACACTCTGTTATTACAAATCG. The genomic transposition sites were located using BLAST programs maintained at the NCBI web site of the National Library of Medicine (<http://www.ncbi.nlm.nih.gov/BLAST/>). The *fldA* mutant had a transposon inserted into the *fldA* coding sequence at nucleotide 39.

2.4. Complementation of the *fldA* mutant

To complement the DK310 *LytB*^{G120D} *fldA⁻* (pTMV20KM) mutant, the *fldA* gene was cloned from *E. coli* into the low-copy vector, pMW118, at the *Bam*HI site to derive the plasmid, pMW-*fldA*. The insert, containing the upstream sequence and the full coding sequence of the *fldA* gene, is given in Supplemental Figure 1. The DK310 *LytB*^{G120D} *fldA⁻* (pTMV20KM) mutant was transformed with the pMW-*fldA* plasmid by electroporation as described above. Transformants were selected by resistance to ampicillin and trimethoprim and then tested for their growth with and without mevalonate.

2.5. Preparing bacterial supernatants and sonicates

To test bacterial supernatants and sonicates for their ability to stimulate Vγ2Vδ2 T cells, *E. coli* bacteria were grown in 1 L of LB media in 2.6 L fluted Fernback flasks to late stationary phase by incubating for ~24 h at 37 °C in an Innova 4400 shaker oscillating at 225 rev/min. This was found to result in the maximum amount of bioactivity. The bacteria were harvested by centrifugation at 380 × *g* for 15 min at 4 °C. The culture supernatant was removed and the bacteria washed twice with phosphate buffered saline (PBS). Bacteria from 1 L of culture were suspended in 10 ml of PBS and continuously probe sonicated for 10 min on ice at a 4.5 setting (Sonic Dismembrator Model 550, Fisher Scientific). The sonicated bacteria were centrifuged at 300 × *g* for 15 min at 4 °C. The supernatants from the sonicated bacteria and the culture supernatants were heated in a boiling water bath for 5 min, cooled on ice for 5 min, centrifuged at 16000 × *g* for 30 min at 4 °C, filter sterilized with a 0.22 µm filter, and frozen at –80 °C. The heating caused precipitation of protein and other bacterial components that inhibit T cell proliferation but did not affect the overall bioactivity for Vγ2Vδ2 T cells.

2.6. Assaying bioactivity for Vγ2Vγ2 T cells

The 12G12, DG.SF68, and CP.1.15 Vγ2Vδ2 T cell clones used in this study have been described [22]. Vγ2Vδ2 T cell clones were propagated by periodic re-stimulation as described [23]. Briefly, 2.5–5 × 10⁵ T cells were cultured with irradiated PBMC (2.5 × 10⁵) from healthy donors, EBV-transformed B cells (DG.EBV and CP.EBV each at 2.5 × 10⁵) and PHA (1:2000) in RPMI 1640 supplemented with rIL-2 (1 nM).

For assaying bioactivity, 5–10 × 10⁴ Vγ2Vδ2 T cells were cultured with 5–10 × 10⁴ mitomycin C-treated Va-2 cells (a transformed human fibrosarcoma cell line) as antigen presenting cells in 200 µl of complete medium (RPMI 1640 with 8% FBS, L-glutamine, sodium pyruvate, non-essential, essential MEM amino acids, HEPES, and β-mercaptoethanol). Culture supernatants and bacterial sonicates were added to the cultures at half-log dilutions and incubated at 37 °C. The cultures were pulsed with 1 µCi of ³H-thymidine after 24 h and harvested 16–24 h later.

Table 1
Growth properties of the DK310 *LytB*^{G120D} mutants^a

Growth condition	DK310 <i>LytB</i> ^{G120D} (pTMV22KM)	DK310 <i>LytB</i> ^{G120D} (pTMV20KM)
CM ^b and KM ^c	–	++
CM, KM, and MVA ^d	++	++
CM, KM, and FMM ^e	–	–
CM, KM, MVA, and FMM	–	+

^aBacteria were grown in LB liquid medium for 12 h at 37 °C.

^bChloramphenicol was present at 34 µg/ml.

^cKanamycin was present at 25 µg/ml.

^dMevalonolactone was present at 0.01%.

^eFosmidomycin was present at 12.5 µg/ml.

To quantitate bioactivity, the dilution of the bacterial supernatant or sonicate that gave half-maximal proliferation was determined. The reciprocal of the dilution gave the units of bioactivity. Therefore, one unit of bioactivity was the antigen amount in 1 ml that gave half-maximal antigen-induced proliferation of a V γ 2V δ 2 T cell clone. This corresponds to an HMBPP concentration of 31.6 pM or 31.6 fmol/ml and an IPP concentration of 3 μ M or 3 nmol/ml. To control for variations in this assay (about 3-fold), a standard preparation of ethylpyrophosphate that contained 12000 U/ml was assayed with each experiment. Bioactivity values were adjusted relative to this standard. Total bioactivity for a 1 L culture was the sum of the bioactivity present in the bacterial sonicates and culture supernatants. For stationary phase and late stationary phase cultures of wild-type *E. coli*, 77% and 95% of the bioactivity was in the supernatant, respectively. In the DK310 *LytB*^{G120D} (pTMV20KM) and DK310 *LytB*^{G120D} *fldA*[−] (pTMV20KM), 91% and 43% of the bioactivity was in the supernatant, respectively.

3. Results and discussion

3.1. Substitution of aspartic acid for glycine at position 120 in *LytB* in DK310 results in the loss of IPP but not DMAPP synthesis

A point mutation was made in the *lytB* gene of DK310 pTMV22KM that lacks isopentenyl diphosphate isomerase by chemical mutagenesis such that aspartic acid was substituted for glycine at residue 120. This residue is in an area that is highly conserved between *E. coli*, *Mycobacterium tuberculosis*, the cyanobacteria, *Synechocystis*, the plant, *Adonis aestivalis*, and the apicomplexan parasite, *Plasmodium falciparum* and near an additional area of conservation around the cysteine residue 96 [4,24]. The mutant, DK310 *LytB*^{G120D} pTMV22KM (*idi*[−]), can synthesize IPP in the presence of mevalonate through the introduced mevalonate pathway enzymes and is mevalonate dependent (Table 1). Since the mutant lacks isopentenyl diphosphate isomerase, it cannot isomerize IPP to DMAPP. This is the only way to interconvert IPP and DMAPP in *E. coli* [25]. Based on this fact, we hypothesize that the *LytB*^{G120D} mutant must continue to synthesize DMAPP but has lost the ability to synthesize IPP.

Consistent with this hypothesis, blocking the MEP pathway with fosmidomycin prevented bacterial growth (Table 1). Moreover, reintroduction of isopentenyl diphosphate isomerase from *Streptomyces* sp. in DK310 *LytB*^{G120D} pTMV20KM (Table 1) restored mevalonate-independent growth and fosmidomycin resistance. Since DMAPP synthesized by *LytB* could isomerize to IPP and IPP synthesized by phosphomevalonate decarboxylase could isomerize to DMAPP, bacterial growth occurred even when each individual pathway was blocked (see Fig. 1).

3.2. Flavodoxin I is essential for isoprenoid biosynthesis

To examine genes that are involved in isoprenoid biosynthesis, the DK310 *LytB*^{G120D} pTMV20KM strain was subjected to random transposon mutagenesis. Mevalonate was introduced to rescue bacteria since mutations in the MEP pathway are lethal in its absence. A total of 27 mutants were selected for their failure to grow independently of MVA. Direct genome sequencing of these mutants reveals that 25 had transposon insertions in genes of enzymes within the MEP pathway. One gene not previously reported to be essential in the MEP pathway was *fldA*. Mutation of *fldA*, as with mutation of all the genes present in the MEP pathway, resulted in the failure




Fig. 1. The MEP (deoxyxylulose) pathway of isoprenoid biosynthesis and the engineered biosynthesis of IPP from exogenous mevalonate [1–4]. Proposed steps of flavodoxin action at GcpE and possibly at *LytB* are shown. MEP enzymes are also termed IspC (Dxr), IspD (YgbP), IspE (YchB), IspF (YgbB), IspG (GcpE), and IspH (*LytB*). The DK310 bacteria were transformed with a plasmid containing the genes for the following mevalonate pathway enzymes: MVK, mevalonate kinase; PMK, phosphomevalonate kinase; MDD, mevalonate diphosphate decarboxylase.

of the mutant to grow on LB agar unless exogenous mevalonate was provided (Fig. 2B and C).

Since the functional activity of GcpE [7,15] and *LytB* [8,16,17,26] depends on the availability of reduced [4Fe–4S]⁺ clusters, a defect in flavodoxin I function appears to block the regeneration of reduced clusters resulting in impaired isoprenoid biosynthesis. Despite the fact that there are $\approx$ 50 iron–sulfur proteins in the genome of *E. coli* [27], deletion of flavodoxin I was not lethal or bacteriostatic as long as exogenous mevalonate was present (Fig. 2B and C). To verify that this phenotype was not the result of a polar effect of the transposon insertion, the *fldA* mutant was complemented with a full-length copy of plasmid-encoded *fldA*. Growth was observed in the *fldA*-complemented mutant in the absence of mevalonate showing that isoprenoid biosynthesis through the MEP pathway was restored (Fig. 2D, G, and H). These results demonstrate that the essential role for flavodoxin I is in the MEP pathway for isoprenoid biosynthesis.




Fig. 2. Mevalonate-independent growth of DK310 LytB^{G120D} (pTMV20KM) is lost after disruption of *fldA* and restored after *fldA* complementation. Panels A–D: Growth of the *E. coli* strains (A) DK310 LytB^{G120D} (pTMV20KM) (termed KM20 on left) and DK310 LytB^{G120D} (pTMV20KM) · *fldA* (termed KM20 · *fldA* on right) on medium (B) without mevalonate, (C) with mevalonate, and (D) without mevalonate after complementation of the KM20 · *fldA* strain with an episomal *fldA* gene. Panels E–H: Growth of KM20 · *fldA* on medium (E) without mevalonate or after complementation with an episomal *fldA* gene (F) with mevalonate, (G) without mevalonate, and (H) without mevalonate but with ampicillin. Note that although complementation of the KM20 · *fldA* strain with an episomal *fldA* gene restored growth without mevalonate, the growth of the complemented bacteria was slower than when growing with mevalonate (compare bacterial growth in panel 2C with panel 2D and panel 2F with panel 2G).

3.3. HMBPP synthesis is *fldA*-dependent

HMBPP is synthesized by GcpE and is the upstream intermediate for IPP and DMAPP in the MEP pathway. HMBPP is ~30 000-fold more antigenic for human Vγ2Vδ2 T cells stimulation than IPP (data not shown and [11,28]). Synthesis of HMBPP through two one-electron transfers catalyzed by the [4Fe–4S] cluster of the GcpE enzyme has been proposed [9]. Like many [Fe–S] proteins, the enzymatic activity of GcpE depends on the presence of a reducing system. The source of these reducing equivalents is either derived from exogenous reductants (dithiothreitol or deazaflavin) or the native endogenous flavodoxin/flavodoxin reductase/NADPH regeneration system.

In the LytB^{G120D} mutant, DK310 LytB^{G120D} (pTMV20KM), HMBPP was overproduced resulting in a large increase of bioactivity (436-fold) for Vγ2Vδ2 T cell as compared to the wild-type *E. coli* (Fig. 3). This is consistent with previous reports showing that *lytB* deletion blocks the downstream synthesis of IPP and DMAPP causing HMBPP to accumulate [11] and large increases in bioactivity for Vγ2Vδ2 T cells [10]. However, the loss of flavodoxin I in the *fldA*[−] double mutant led to wild-type levels of bioactivity for Vγ2Vδ2 T cells. Thus, the loss of flavodoxin greatly impairs the ability of GcpE to make HMBPP suggesting that the flavodoxin regeneration system is critical for providing reducing equivalents for the [4Fe–4S] cluster. Although greatly reduced, the bioactivity of the *fldA*[−] double mutant is still higher than two corresponding *gcpE* transposon mutants (<500 and 1044 U/L) and a *gcpE* deletion mutant [29] suggesting that there may be some residual activity of the GcpE enzyme. The LytB enzyme also depends on a

[4Fe–4S] cluster for enzymatic activity so the loss of flavodoxin I may also affect LytB function. In summary, the essential role for flavodoxin I is to provide reducing equivalents for the [4Fe–4S] cluster of GcpE and possibly LytB. Both of these enzymes are critical for the growth of *E. coli* under aerobic conditions in rich media.




Fig. 3. Loss of flavodoxin I in DK310 LytB^{G120D} (pTMV20KM) decreased HMBPP to the levels of wild-type *E. coli* as assessed by bioactivity for Vγ2Vδ2 T cells. Wild-type *E. coli*, DK310 LytB^{G120D} (pTMV20KM), and DK310 LytB^{G120D} (pTMV20KM) *fldA*[−] were grown to late stationary phase. Bioactivity for Vγ2Vδ2 T cells was quantitated for bacterial culture supernatants and sonicates using Vγ2Vδ2 T cell clones in an in vitro proliferation assay. Note that the greatly elevated bioactivity of DK310 LytB^{G120D} (pTMV20KM) that have been shown to be due to accumulation of HMBPP [11] was reduced to wild-type levels. Since one unit of bioactivity corresponds to an HMBPP concentration of ~31.6 pM or 31.6 fmol/ml, wild-type bacteria, DK310 LytB^{G120D} (pTMV20KM), and DK310 LytB^{G120D} (pTMV20KM) *fldA*[−] had bioactivity equivalent to 0.6, 250.3, and 0.7 μmol of HMBPP, respectively.

Acknowledgments: We thank E. Oldfield, G. Sarikonda, and A. Raker for critical reading of the manuscript. We thank S. Matsuyama of Rikkyo University for providing pTTQ18 and H. Ikeda of Kitasato University for providing pKC7. This work was supported by the National Institutes of Health, NIAMS division (NIH Grant AR045504 to C.T.M.).

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.febslet.2005.05.047](https://doi.org/10.1016/j.febslet.2005.05.047).

References

- [1] Rohmer, M. (2003) Mevalonate-independent methylerythritol phosphate pathway for isoprenoid biosynthesis. Elucidation and distribution. *Pure Appl. Chem.* 75, 375–387.
- [2] Kuzuyama, T. (2002) Mevalonate and nonmevalonate pathways for the biosynthesis of isoprene units. *Biosci. Biotechnol. Biochem.* 66, 1619–1627.
- [3] Kuzuyama, T. and Seto, H. (2003) Diversity of the biosynthesis of the isoprene units. *Nat. Prod. Rep.* 20, 171–183.
- [4] Rohdich, F., Bacher, A. and Eisenreich, W. (2004) Perspectives in anti-infective drug design. The late steps in the biosynthesis of the universal terpenoid precursors, isopentenyl diphosphate and dimethylallyl diphosphate. *Bioorg. Chem.* 32, 292–308.
- [5] Altincicek, B., Kollas, A.-K., Sanderbrand, S., Wiesner, J., Hintz, M., Beck, E. and Jomaa, H. (2001) GcpE is involved in the 2-C-methyl-D-erythritol 4-phosphate pathway of isoprenoid biosynthesis in *Escherichia coli*. *J. Bacteriol.* 183, 2411–2416.
- [6] Hecht, S., Eisenreich, W., Adam, P., Amslinger, S., Kis, K., Bacher, A., Arigoni, D. and Rohdich, F. (2001) Studies on the nonmevalonate pathway to terpenes: the role of the GcpE (IspG) protein. *Proc. Natl. Acad. Sci. USA* 98, 14837–14842.
- [7] Kollas, A.-K., Duin, E.C., Eberl, M., Altincicek, B., Hintz, M., Reichenberg, A., Henschker, D., Henne, A., Steinbrecher, I., Ostrovsky, D.N., Hedderich, R., Beck, E., Jomaa, H. and Wiesner, J. (2002) Functional characterization of GcpE, an essential enzyme of the non-mevalonate pathway of isoprenoid biosynthesis. *FEBS Lett.* 532, 432–436.
- [8] Altincicek, B., Duin, E.C., Reichenberg, A., Hedderich, R., Kollas, A.-K., Hintz, M., Wagner, S., Wiesner, J., Beck, E. and Jomaa, H. (2002) LytB protein catalyzes the terminal step of the 2-C-methyl-D-erythritol-4-phosphate pathway of isoprenoid biosynthesis. *FEBS Lett.* 532, 437–440.
- [9] Seemann, M., Bui, B.T., Wolff, M., Tritsch, D., Campos, N., Boronat, A., Marquet, A. and Rohmer, M. (2002) Isoprenoid biosynthesis through the methylerythritol phosphate pathway: the (E)-4-hydroxy-3-methylbut-2-enyl diphosphate synthase (GcpE) is a [4Fe-4S] protein. *Angew. Chem., Int. Ed. Engl.* 41, 4337–4339.
- [10] Eberl, M., Altincicek, B., Kollas, A.-K., Sanderbrand, S., Bahr, U., Reichenberg, A., Beck, E., Foster, D., Wiesner, J., Hintz, M. and Jomaa, H. (2002) Accumulation of a potent $\gamma\delta$ T-cell stimulator after deletion of the *lytB* gene in *Escherichia coli*. *Immunology* 106, 200–211.
- [11] Hintz, M., Reichenberg, A., Altincicek, B., Bahr, U., Gschwind, R.M., Kollas, A.-K., Beck, E., Wiesner, J., Eberl, M. and Jomaa, H. (2001) Identification of (E)-4-hydroxy-3-methylbut-2-enyl pyrophosphate as a major activator for human $\gamma\delta$ T cells in *Escherichia coli*. *FEBS Lett.* 509, 317–322.
- [12] Morita, C.T., Mariuzza, R.A. and Brenner, M.B. (2000) Antigen recognition by human $\gamma\delta$ T cells: pattern recognition by the adaptive immune system. *Springer Semin. Immunopathol.* 22, 191–218.
- [13] Begley, M., Gahan, C.G., Kollas, A.-K., Hintz, M., Hill, C., Jomaa, H. and Eberl, M. (2004) The interplay between classical and alternative isoprenoid biosynthesis controls $\gamma\delta$ T cell bioactivity of *Listeria monocytogenes*. *FEBS Lett.* 561, 99–104.
- [14] Eberl, M., Hintz, M., Reichenberg, A., Kollas, A.-K., Wiesner, J. and Jomaa, H. (2003) Microbial isoprenoid biosynthesis and human $\gamma\delta$ T cell activation. *FEBS Lett.* 544, 4–10.
- [15] Rohdich, F., Zepeck, F., Adam, P., Hecht, S., Kaiser, J., Laupitz, R., Gräwert, T., Amslinger, S., Eisenreich, W., Bacher, A. and Arigoni, D. (2003) The deoxyxylulose phosphate pathway of isoprenoid biosynthesis: studies on the mechanisms of the reactions catalyzed by IspG and IspH protein. *Proc. Natl. Acad. Sci. USA* 100, 1586–1591.
- [16] Wolff, M., Seemann, M., Tse Sum Bui, B., Frapart, Y., Tritsch, D., Garcia Estrabot, A., Rodríguez-Concepción, M., Boronat, A., Marquet, A. and Rohmer, M. (2003) Isoprenoid biosynthesis via the methylerythritol phosphate pathway: the (E)-4-hydroxy-3-methylbut-2-enyl diphosphate reductase (LytB/IspH) from *Escherichia coli* is a [4Fe-4S] protein. *FEBS Lett.* 541, 115–120.
- [17] Gräwert, T., Kaiser, J., Zepeck, F., Laupitz, R., Hecht, S., Amslinger, S., Schramek, N., Schleicher, E., Weber, S., Haslbeck, M., Buchner, J., Rieder, C., Arigoni, D., Bacher, A., Eisenreich, W. and Rohdich, F. (2004) IspH protein of *Escherichia coli*: studies on iron-sulfur cluster implementation and catalysis. *J. Am. Chem. Soc.* 126, 12847–12855.
- [18] Gaudy, P. and Weiss, B. (2000) Flavodoxin mutants of *Escherichia coli* K-12. *J. Bacteriol.* 182, 1788–1793.
- [19] Takahashi, S., Kuzuyama, T., Watanabe, H. and Seto, H. (1998) A 1-deoxy-D-xylulose 5-phosphate reductoisomerase catalyzing the formation of 2-C-methyl-D-erythritol 4-phosphate in an alternative nonmevalonate pathway for terpenoid biosynthesis. *Proc. Natl. Acad. Sci. USA* 95, 9879–9884.
- [20] Takagi, M., Kuzuyama, T., Takahashi, S. and Seto, H. (2000) A gene cluster for the mevalonate pathway from *Streptomyces* sp. Strain CL190. *J. Bacteriol.* 182, 4153–4157.
- [21] Kaneda, K., Kuzuyama, T., Takagi, M., Hayakawa, Y. and Seto, H. (2001) An unusual isopentenyl diphosphate isomerase found in the mevalonate pathway gene cluster from *Streptomyces* sp. strain CL190. *Proc. Natl. Acad. Sci. USA* 98, 932–937.
- [22] Tanaka, Y., Sano, S., Nieves, E., De Libero, G., Roca, D., Modlin, R.L., Brenner, M.B., Bloom, B.R. and Morita, C.T. (1994) Nonpeptide ligands for human $\gamma\delta$ T cells. *Proc. Natl. Acad. Sci. USA* 91, 8175–8179.
- [23] Morita, C.T., Verma, S., Aparicio, P., Martinez, C.A., Spits, H. and Brenner, M.B. (1991) Functionally distinct subsets of human $\gamma\delta$ T cells. *Eur. J. Immunol.* 21, 2999–3007.
- [24] Cunningham Jr., F.X., Lafond, T.P. and Gantt, E. (2000) Evidence of a role for LytB in the nonmevalonate pathway of isoprenoid biosynthesis. *J. Bacteriol.* 182, 5841–5848.
- [25] Rodríguez-Concepción, M., Campos, N., Maria Lois, L., Maldonado, C., Hoeffler, J.F., Grosdemange-Billiard, C., Rohmer, M. and Boronat, A. (2000) Genetic evidence of branching in the isoprenoid pathway for the production of isopentenyl diphosphate and dimethylallyl diphosphate in *Escherichia coli*. *FEBS Lett.* 473, 328–332.
- [26] Seemann, M., Wegner, P., Schunemann, V., Bui, B.T., Wolff, M., Marquet, A., Trautwein, A.X. and Rohmer, M. (2005) Isoprenoid biosynthesis in chloroplasts via the methylerythritol phosphate pathway: the (E)-4-hydroxy-3-methylbut-2-enyl diphosphate synthase (GcpE) from *Arabidopsis thaliana* is a [4Fe-4S] protein. *J. Biol. Inorg. Chem.* 14, 14.
- [27] Tokumoto, U. and Takahashi, Y. (2001) Genetic analysis of the *isc* operon in *Escherichia coli* involved in the biogenesis of cellular iron-sulfur proteins. *J. Biochem. (Tokyo)* 130, 63–71.
- [28] Reichenberg, A., Hintz, M., Kletschek, Y., Kuhl, T., Haug, C., Engel, R., Moll, J., Ostrovsky, D.N., Jomaa, H. and Eberl, M. (2003) Replacing the pyrophosphate group of HMB-PP by a diphosphonate function abrogates its potential to activate human $\gamma\delta$ T cells but does not lead to competitive antagonism. *Bioorg. Med. Chem. Lett.* 13, 1257–1260.
- [29] Altincicek, B., Moll, J., Campos, N., Foerster, G., Beck, E., Hoeffler, J.F., Grosdemange-Billiard, C., Rodríguez-Concepción, M., Rohmer, M., Boronat, A., Eberl, M. and Jomaa, H. (2001) Human $\gamma\delta$ T cells are activated by intermediates of the 2-C-methyl-D-erythritol 4-phosphate pathway of isoprenoid biosynthesis. *J. Immunol.* 166, 3655–3658.